摘要
目的探讨保妇康栓治疗宫颈糜烂人乳头状瘤病毒(HPV)感染的临床疗效及安全性,为临床资料提供参考依据。方法选取2011年9月-2013年9月科室确诊患有宫颈糜烂HPV感染以及宫颈柱状上皮外移患者120例,随机分为A组、B组及C组,各40例,A组使用保妇康栓治疗、B组使用重组人干扰素α-2a阴道栓治疗、C组未用药物治疗,对比3组患者宫颈糜烂治疗结果、HC2结果以及不良反应,所得数据采用SPSS 13.0进行分析。结果 A组治愈占57.50%、显效占30.00%、好转占12.50%;B组治愈占37.50%、显效占27.50%、好转占35.00%,A组治疗效果优于B组,差异有统计学意义(P<0.05);C组无治愈病例,B组治疗效果优于C组患者,差异有统计学意义(P<0.05);HC2转阴率A组97.50%、B组85.00%,A组明显好于B组,差异有统计学意义(P<0.05),B组HC2转阴率优于C组的30.0%,差异有统计学意义(P<0.05),3组患者均无严重不良反应发生。结论保妇康栓治疗宫颈糜烂HPV感染疗效确切显著、不良反应小,值得临床推广应用。
OBJECTIVE To investigate clinical efficacy and safety of Baofukang suppository in treatment of cervical erosion combined with human papillomavirus (HPV) infection. METHODS A total of 120 patients diagnosed with cervical HPV infection and cervical columnar epithelium relocation during Sept. 2011 to Sept. 2013 were randomly divided into group A, group B and group C with 40 cases in each group. Women of group A received treatment with Baofukang suppository, group B with recombinant human interferon a-2a vaginal suppository, group C did not received any medication. The therapeutic results for cervical erosion, HC2 (hybrid capture Ⅱ ) results and adverse reactions were compared between the three groups. Data obtained were analyzed using the software SPSS 13.0. RESULTS The curative, effective, and improved rate was 57.50%, 30.00%, 12. 50% in group A, and 37.50%, 27.50%, 35.00% in group B, indicating that the treatment efficacy was better in group A than in group B, the difference was significant (P〈0. 05). Group C had no cured cases. The treatment efficacy was better in group B than in group C, the difference was significant (P 〈0.05). The negative conversion ratio of HC2 in group A (97.50%) was significantly higher than in group B (85.00%) (P〈0.05). The negative conversion ratio of HC2 in group B was superior to group C, the difference was significant (P〈0.05). There were no serious adverse reactions in the three groups. CONCLUSION Treatment of Baofukang suppository for cervical erosion combined with HPV infection resulted in significant efficacy and few adverse reactions, which was worthy of clinical application.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2014年第8期2037-2038,2041,共3页
Chinese Journal of Nosocomiology
基金
浙江省卫生厅医药卫生计划基金资助项目(2011ZDA015)
关键词
保妇康栓
宫颈糜烂
人乳头状瘤病毒
临床疗效
Baofukang suppository
Cervical erosion
Human papillomavirus
Clinical efficacy